|
Pulmonology
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
Soo Han Kim, Eun Jung Jo, Jeongha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Jung Seop Eom, Mi-Hyun Kim
Korean J Intern Med. 2023;38(2):218-225. Published online February 21, 2023
Background/Aims: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce.
Methods: This retrospective study included 89 patients with ES-SCLC treated with ..
|
|
|
The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma
Sang-Heon Kim, Hyun Lee, So-Young Park, So Young Park, Woo-Jung Song, Joo-Hee Kim, Heung-Woo Park, You Sook Cho, Ho Joo Yoon; on behalf of the KoSAR investigators
Korean J Intern Med. 2022;37(2):249-260. Published online February 28, 2022
Severe asthma constitutes a serious health burden with significant morbidity and socioeconomic costs. The development and introduction of new biologics targeting type 2 inflammation changed the paradigm for management of severe asthma and initiated a biological era. These changes impose a challenge ..
|
|
|
Current status of heart failure: global and Korea
Jin Joo Park, Dong-Ju Choi
Korean J Intern Med. 2020;35(3):487-497. Published online April 29, 2020
Heart failure (HF) is a condition in which the heart is unable to pump enough blood to meet the body’s needs for blood and oxygen. Thus, HF is a grave disease with high morbidity and mortality. Because the prevalence of and exposure to the risk factors for HF increase with age, the prevalence of H..
|
|
|
Gastroenterology
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Korean J Intern Med. 2019;34(4):794-801. Published online May 25, 2018
Background/Aims: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patient..
|
|
|
